Trial Profile
Phase II study of CC-5103 [lenalidomide] and rituximab in Waldenstrom's macroglobulinemia.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 15 Dec 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.